Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tomorrow we go higher! I'm still in, since Sept. 08! GLTA
.0003 is up!!!
GM All, nice buying coming in again!
I agree. Nice Chart hang ten, Thanks.
The same to you, buddy!
3 minutes to late -> .135 with 100 shares, printing!
c'mon HOD close, please!
If we close green today, we will run again till .20 without NEWS!
Someone is buying big blocks!
Hope so, i bought more @ .1135! GLTA
GM All, great day, yesterday!
hopefully we will test the $2.00 today! GLTA
great close again!
Bad Day! We need NEWS!
maybe we hit the $1.00 again!? GLTY
Nice pre market volume!
Nice BID support @ .83!
Therapeutic Antibodies: Potential to Revolutionize Treatment of Autoimmune Diseases
* On Sunday May 31, 2009, 11:45 pm EDT
......
In the following brief excerpt from the 107 page report, the CEO of Xoma discuss the outlook for using therapeutic antibodies for the treatment of autoimmune diseases.
TWST: Please begin with a brief historical sketch of the company and a picture of the things you are doing at the present time.
Mr. Engle: We are a recognized leader in the discovery and development of therapeutic antibodies. Our lead product, XOMA 052, is a potentially revolutionary treatment for the inflammatory cause of many major diseases including Type II diabetes, cardiovascular disease and autoimmune diseases. In addition, XOMA receives revenues from: the licensing of its antibody technologies to over 50 companies; product royalties (LUCENTIS and CIMZIA); development collaborations with Takeda, Novartis and Schering-Plough; and biodefense contracts. Based in Berkeley, California, XOMA has 200 employees.Our lead product candidate, XOMA 052, is a proprietary antibody that regulates production of the cytokine called interleukin-1 or IL-1, which is the master cytokine in activating the inflammatory cascade. We recently received a US patent for XOMA 052, providing an important acknowledgement that it has properties that differentiate it from other agents that target IL-1. We recently completed enrollment in Phase I studies of XOMA 052 in Type II diabetes and plan to announce top-line results from the US trial in July. The trials evaluated a wide range of XOMA 052 doses, single and multiple dose regimens, and intravenous and subcutaneous routes of administration. Interim results presented last fall from the single dose IV trials demonstrated that XOMA 052 is well tolerated across all doses. Further, XOMA 052 showed evidence of biological activity, including reduced levels of glycosylated hemoglobin, increased insulin production and reduced levels of C-reactive protein, or CRP, compared to placebo. CRP is a well-established marker for the systemic inflammation associated with cardiovascular disease, one of the largest pharmaceutical markets. For this reason, we have begun to evaluate XOMA 052 for its potential cardiovascular benefits in addition to considering it for development in diabetes and autoimmune diseases. In addition to XOMA 052 and the other products in our proprietary pipeline, we have a business focused on collaborations with other companies using our broad antibody technologies, a business focused on biodefense funded by the US government, and a royalty-based business based on our pioneering position in developing antibodies for therapeutic uses. We currently receive royalties on sales of LUCENTIS from Genentech and CIMZIA from UCB.
TWST: Would you sketch out your strategic agenda for the next two to three years?
Mr. Engle: We are very focused on advancing the development of XOMA 052 for diabetes and cardiovascular disease because it is a revolutionary approach and has the greatest single potential for maximizing the return to shareholders. Discussions toward a corporate partnership for XOMA 052 are underway and we plan to finalize this partnership by year-end. We plan to advance XOMA 052 for other indications and continue bringing forward the other proprietary compounds we have in pre-clinical development. With the advancement of XOMA 052, establishment of a corporate partnership, advancement of our pre-clinical pipeline and our other businesses, we believe we have multiple opportunities to significantly grow shareholder value.
The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.
For Information on subscribing to The Wall Street Transcript, please call 800/246-7673
Great close @ .81!
GM DF and all! what's going on, pre market 5k @.185!
good job EP!
GM All, more then 222.000 shares bought in the last 5 minutes yesterday! and only 500 shares sold! GREAT
Something cooking! imo
GLTA
GM All, Nice turnaround yesterday, with good News! GLTA
great close!!! :eek:
GM DF and All,
nice pre market action @.17!!!
Look at the OTCBB.com dailylist. JNIP under SYMBOL CHANGE CANCELLATIONS
http://www.otcbb.com/asp/dailylist_detail.asp?d=05/22/2009&mkt_ctg=OTCBB
green close! have a nice weekend!
GM All, hopefully we get a green day!
INSIDER BUYING: Form 4 Filings 5/21/09
http://www.secform4.com/insider-trading/791908.htm
Hi All,
volume comming back with lots of buying today, Nice!
Yep, see you tomorrow!
our time will come, we have to wait!
Morning DF!
5,6 million here!
Yep, still in, since Sept.08!
Damn, even close again! See you @ bell, Good Night, DF!
GREEN, huge BID SUPPORT!
NEWS pending? GL
Nice buying pressure coming in!
About Us: OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.
OrbiMed's investment team includes over 25 experienced professionals with backgrounds in science, medicine, industry, finance and law. The firm's diverse team of professionals has a unique understanding of industry dynamics through active participation in both public and private companies. Our professionals work together in a collaborative, team-oriented approach which seamlessly integrates our public and private equity platforms. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. Where appropriate, particularly within its venture capital funds, OrbiMed supports its portfolio companies in achieving strategic, financial and operational objectives via participation at the Board of Directors level. OrbiMed professionals currently serve on the Board of Directors of dozens of different life sciences companies.
History
Life Cycle Investing
Funds
Life Sciences
OrbiMed & the Caduceus
Industry Links
© 2009 OrbiMed Advisors, LLC Home | Privacy | Legal | Site Map
Good Night, DF, see you tomorrow.
GM DF, we need good NEWS!